Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLK | P51451 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496280 | 0.89 | KDR (0.53) | ALDH1A1ACLYKDRGAAPRKCI | |
| SCHEMBL1496284 | 0.88 | KDR (0.52) | ALDH1A1SMN1; SMN2ACLYKDRGAA | |
| SCHEMBL1496290 | 0.87 | NPC1 (0.55) | ALDH1A1SMN1; SMN2ACLYKDRKMT2A | |
| SCHEMBL1496291 | 0.86 | KDM4E (0.47) | ALDH1A1SMN1; SMN2ACLYKDRGAA | |
| SCHEMBL1496354 | 0.86 | ACLY (0.43) | ALDH1A1ACLYKDRGAAPABPC1 | |
| SCHEMBL1496367 | 0.84 | KDR (0.53) | ALDH1A1ACLYKDRGAADNMT1 | |
| SCHEMBL1496366 | 0.83 | KDR (0.66) | ALDH1A1ACLYKDRGAAPABPC1 | |
| SCHEMBL1496313 | 0.82 | KDM4E (0.45) | BLKALDH1A1ACLYKDRGAA | |
| SCHEMBL1496312 | 0.82 | KMT2A (0.47) | BLKALDH1A1ACLYKDRGAA | |
| SCHEMBL1496325 | 0.82 | MEN1 (0.52) | ALDH1A1SMN1; SMN2ACLYKDRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | claimed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SQOR, QSOX1, SQLE | BLK 1348/4885ALDH1A1 1108/4885SMN1; SMN2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.